Clinical trials: Relapsed
Relapsed / Refractory Autoimmune Hemolytic Anemia
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Autoimmune Hemolytic Anemia
This is an open label, single-site, dose-escalation study in up to 18 participants with relapsed or refractory Autoimmune hemolytic anemia.
- Trial name
- NCT06920446
- Testing
- UCAR T-cell group
- Volunteers
- 18 people
- Sponsor
- Zhejiang University
Leukemia
Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
RATIONALE: Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of panobinostat and to see how well it works in…
- Trial name
- NCT00723203
- Testing
- panobinostat, gene expression analysis, reverse transcriptase-polymerase chain reaction
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia
ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia
This phase I/II trial studies the side effects and best dose of ABBV-383 and to see how well it works in treating patients with Waldenström macroglobulinemia that has come back after a period of improvement (relapsed) or that…
- Trial name
- NCT07420959
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Multiple Sclerosis
PET Study in Multiple Sclerosis
While both conventional and advanced MRI techniques offer important insights into MS pathophysiology, important aspects of this inflammatory disorder are undetectable with existing MRI technology.
- Trial name
- NCT03787446
- Where
- Canada
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Solid Tumor, Lymphoma
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas
The potency of immune checkpoint blockade is limited in most solid malignancies, one possible reason for which is tumor microenvironment.
- Trial name
- NCT04407741
- Testing
- SHR2554+SHR1701, SHR1701
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
Chronic Myeloproliferative Disorders, Leukemia
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine, and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00290641
- Testing
- filgrastim, graft-versus-tumor induction therapy, cyclophosphamide
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Recurrent Extragonadal Seminoma, Recurrent Malignant Extragonadal Germ Cell Tumor
Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors
This phase II trial is studying alvocidib and oxaliplatin to see how well they work when given with or without fluorouracil and leucovorin calcium in treating patients with relapsed or refractory germ cell tumors.
- Conditions
- Recurrent Extragonadal Seminoma, Recurrent Malignant Extragonadal Germ Cell Tumor, Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor, Recurrent Malignant Testicular Germ Cell Tumor
- Trial name
- NCT00957905
- Testing
- Alvocidib Hydrochloride, Fluorouracil, Leucovorin Calcium
- Where
- 10 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Sclerosis, Relapsing-Remitting
Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic immune central nervous system (CNS) disease of unknown cause. Recent studies suggest that gut microbiota could be a trigger for the neuro-inflammation in MS and abnormal gut microbiota…
- Trial name
- NCT03975413
- Testing
- Fecal Microbiota Transplantation (FMT)
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Rush University Medical Center
Leukemia, Lymphoma
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer
RATIONALE: Biological therapy using growth factors may be effective in reducing side effects in patients who have hematologic cancer and are receiving radiation therapy, chemotherapy, and peripheral stem cell transplantation.
- Conditions
- Leukemia, Lymphoma, Oral Complications
- Trial name
- NCT00004061
- Testing
- filgrastim, palifermin, cyclophosphamide
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed or Refractory Acute Myeloid Leukemia
Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia
Recent preclinical and retrospective clinical data have suggested that dexamethasone might sensitize leukemic cells to chemotherapy-induced cell death and thus limit the risk of leukemic regrowth and relapse.
- Trial name
- DEXAML-03 (NCT03765541)
- Testing
- Dexamethasone, Amsacrine, Cytarabine
- Where
- 10 sites in France
- Volunteers
- 73 people
- Sponsor
- University Hospital, Toulouse
Advanced Solid Tumors, Ovarian Cancer
A Study of PHST001 in Advanced Solid Tumors
This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination…
- Conditions
- Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma
- Trial name
- NCT06840886
- Testing
- PHST001, Paclitaxel, Topotecan
- Where
- 20 sites in United States
- Volunteers
- 426 people
- Sponsor
- Pheast Therapeutics
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)
The goal of this clinical research study is to learn if daratumumab can help to control B- or T-cell acute lymphoblastic leukemia (ALL). The safety of daratumumab will also be studied. This is an investigational study.
- Trial name
- NCT03207542
- Testing
- Daratumumab
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00812669
- Testing
- pegfilgrastim, rituximab, cyclophosphamide
- Where
- 7 sites in Ireland
- Volunteers
- 52 people
- Sponsor
- Cancer Trials Ireland
Orthodontic Relapse, Retention in Orthodontic
Effectiveness, Patient Acceptance, and Cost Estimation of 3D-printed Retainer Compared to Hawley Retainer in Expansion Case: a Randomized Controlled Trial
Expansion of the arches is generally considered highly unstable and prone to relapse regardless of the type of expansion. Retention appliances play a vital role in preserving these changes.
- Trial name
- NCT07659041
- Testing
- 3D printed retainer, Hawley retainer
- Where
- 3 sites in Malaysia
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- National University of Malaysia
Multiple Myeloma
A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR
CC-5013-PASS-TR/A non-interventional, multi-center, observational post authorization safety study of patients with relapsed/refractory multiple myeloma treated with Lenalidomide in Turkey.
- Trial name
- NCT02387879
- Where
- 38 sites in Turkey (Türkiye)
- Volunteers
- 500 people
- Sponsor
- Celgene
Acute Lymphoblastic Leukemia (ALL)
Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia
This was a Phase 2, international, multicenter, open-label, single-arm trial evaluating Marqibo (VSLI) in adult subjects with: 1) Ph- ALL or lymphoblastic lymphoma in second or greater relapse; or 2) Ph- ALL or lymphoblastic…
- Trial name
- NCT00495079
- Testing
- Marqibo® (vincristine sulfate liposomes injection)
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 65 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Relapsing-Remitting Multiple Sclerosis
Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis
The main purpose of the study is to assess patient-reported satisfaction with subcutaneous (s.c.) ocrelizumab administration in participants with relapsing-remitting multiple sclerosis (RRMS) who are treatment-naive, switching…
- Trial name
- SONATA-MS (NCT07827586)
- Testing
- Ocrelizumab
- Where
- 2 sites in Czechia, Slovenia
- Volunteers
- 1,800 people
- Sponsor
- Hoffmann-La Roche
Relapsing-remitting Multiple Sclerosis
Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis
There are two standard and a few second line treatments for RRMS. Since the disease cannot be cured by these existing treatments and all treatment options have significant limitations, there is the need to develop new treatment…
- Trial name
- RESI (NCT02364986)
- Testing
- Rebif®, Avonex
- Where
- 2 sites in Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- PD Dr. Marcus Müller
Lung Cancer, Relapse/Recurrence
Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial
For patients with lung cancer who have undergone tumor resection, early relapse significantly impacts survival. However, there are currently no reliable screening or imaging tools available to identify patients at risk of early…
- Trial name
- NCT06262386
- Testing
- Cisplatin based chemottherapy
- Where
- Taiwan
- Volunteers
- 358 people
- Sponsor
- Chang Gung Memorial Hospital
Acute Myeloid Leukemia (AML)
Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia
This study is a single-arm, open-label, dose-escalating trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of anti human CI-135 (FLT3) CAR-T Injection , and to preliminarily observe the…
- Trial name
- NCT06760260
- Testing
- Human Derived anti-CI135 CAR-T Injection
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.